This study is designed to test a new combination of three medications, of which only one has been approved for treating HIV infection. All 3 drugs are FDA approved for various conditions.

The first drug, Hydroxychloroquine, is routinely prescribed for some arthritic conditions with an excellent safety profile. Hydroxychloroquine reduced HIV viral load, with little drug resistance, in early clinical trials of HIV+ volunteers.

The other two drugs–Hydroxyurea (a cancer drug) and ddI (an anti-HIV drug)–are often prescribed together as components of a larger anti-HIV combination therapy.

A Phase I/II, open-label, 8-week study with a 6-month extension. There is no placebo group–all participants receive drug. Eye exams will be performed during the study. The study has three cohorts (groups):

• Participants with little prior cocktail therapy ("HAART")
• Participants whose cocktail therapies have failed and are not currently taking any medications
• Participants who are currently on an anti-HIV "drug holiday"

• HIV+ man or woman, at least 18 years old.
• Viral load requirement varies by cohort.
• T-cell count requirement varies by cohort.
• Women who are not pregnant and are willing to use contraceptives for the duration of the study.

Enrolling
--